A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
S. Margolin, L. Carlsson, M. Hellstrom, P. Karlsson, E. Lidbrink, B. Linderholm, H. Lindman, P. Malmstrom, D. Skold Pettersson, J. BerghVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70548-2
File:
PDF, 71 KB
english, 2008